Emerging treatments
Ofatumumab
Ofatumumab is an anti-CD20 biological agent that can be self-administered. It has promise for the at-home or clinic-based administration of anti-CD20 therapy without the infusion requirements associated with rituximab. In one small cohort study, 94% (15/16) of patients who received ofatumumab plus a systemic corticosteroid were in complete remission at 36 weeks, compared with 14% (3/22) of patients who received azathioprine plus a systemic corticosteroid.[53]
Desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART)
DSG3-CAART has received fast track designation from the US Food and Drug Administration (FDA) for the treatment of mucosal pemphigus vulgaris. DSG3-CAART improves healing of mucosal blisters by targeting and killing the B cells that express pathogenic autoantibodies, while preserving the healthy B cells critical to immune function. A phase 1 trial is underway to establish the maximum tolerated dose and the incidence of adverse events.[54]
Use of this content is subject to our disclaimer